To evaluate the comparative effectiveness of antiviral drugs in adults with chronic hepatitis B monoinfection for evidence-based decision-making. METHODS: A systematic review of randomized controlled clinical trials (RCTs) published in English. Results after interferon and nucleos(t)ides analog therapies were synthesized with random-effects meta-analyses and number needed to treat (NNT). RESULTS: Despite sustained improvements in selected biomarkers, no one drug regimen improved all intermediate outcomes. In 16 underpowered RCTs, drug treatments did not reduce mortality, liver cancer, or cirrhosis. Sustained HBV DNA clearance was achieved in one patient when two were treated with adefovir (NNT from 1 RCT=2 95%CI 1;2) or interferon alfa-2b (NNT from 2 RCTs=2 95%CI 2;4), 13 with lamivudine (NNT from 1 RCT=13 95%CI 7;1000), and 11 with peginterferon alfa-2a vs. lamivudine (NNT from 1 RCT=11 95%CI 7;25). Sustained HBeAg seroconversion was achieved in one patient when eight were treated with interferon alfa-2b (NNT from 2 RCTs= 8 95%CI 5;33) or 10-with peginterferon alfa-2b vs. interferon alfa-2b (NNT from 1 RCT = 10 95%CI 5;1000). Greater benefits and safety after entecavir vs. lamivudine or pegylated interferon alfa-2b vs. interferon alfa-2b require future investigation of clinical outcomes. Adverse events were common and more frequent after interferon. Treatment utilization for adverse effects is unknown. 
INTRODUCTION
Chronic hepatitis B infection (CHB) afflicts over 1 million adults in the United States alone and presents a significant public health problem 1 . Treatment goals include prevention of cirrhosis, liver decompensation, and hepatocellular carcinoma 2, 3 that cause an estimated 2,000 to 4,000 deaths annually; over $1 billion is spent per year on hepatitis B-related hospitalizations. Although we do not have good evidence that antiviral drugs can prevent overall mortality, liver-specific mortality, or development of hepatocellular carcinoma in patients with chronic hepatitis B 2, 4 , therapeutic nihilism is difficult to justify as this is a potentially dangerous disease 5 .
Physicians and patients have to make decisions based on benefits of antiviral drugs on virologic, biochemical, and histologic markers including hepatitis B virus (HBV) deoxyribonucleic acid (DNA) clearance, HBeAg loss or seroconversion, decreases in alanine aminotransferase (ALT) levels, and improvement in liver histology 1, 2, 4, 6 . The National Institutes of Health (NIH) consensus development conference synthesized evidence from available research suggesting feasible intermediate endpoints 3, 7 and harms of interferon 8 and nucleos(t)ides analog therapies 9 . The aim of this report is to present a comprehensive analysis of the benefits and harms of antiviral drug therapies for HBeAg positive CHB mono infection in terms of available intermediate outcomes. In addition to the systematic review on the management of chronic HBV infec- 
METHODS
In our analytical framework we examined pooled rates, relative risks, and absolute risk differences in intermediate outcomes sion, viral load of HBV deoxyribonucleotide acid (HBV DNA), ALT levels, histological necroinflammatory and fibrosis scores 17 , and adverse events after antiviral drugs, including interferon alfa-2b, pegylated interferon alfa-2a, lamivudine, adefovir, entecavir, telbivudine, and tenofovir. We used the following definitions for intermediate biomarkers: & Resistance was defined as worsening of histological scores or persistent HBV DNA load, or rates of genetic mutations.
We prioritized HBsAg loss or seroconversion (diagnostic marker of resolved hepatitis) and improvement in histological necroinflammatory scores without worsening in fibrosis scores (diagnostic markers of liver cirrhosis) 3, 18 . We focused on sustained improvement in biomarkers at follow up off the treatments 3, 19 . Our review focuses on HBeAg-positive patients since we previously reported effects of antiviral drugs on HBeAg-negative patients 4 .
We analyzed study quality using the following criteria: subject selection, length and loss of follow-up, adjustment for confounding factors in observational studies and intention to treat principle in clinical trials, masking treatment status, randomization scheme and adequacy, allocation concealment, and justification of sample sizes in RCTs 10, 20 . The protocol for the meta-analyses was created according to recommendations for meta-analysis of RCTs 21, 22 . Meta-analysis was used to assess the consistency of the association between treatments and outcomes using the DerSimonian-Laird inverse-variance weighting method, and random effects models 23 . We chose the random effects models to incorporate differences across trials in patient populations, baseline rates of the outcomes, dosing of drugs, and other factors in the pooled analysis. For pooled relative risks and absolute risk differences we excluded trials with no events in both groups and added a correction coefficient of 0.5 in the trials with no events only in one group. Statistical heterogeneity was assessed by calculating the percent of the total variance due to between-study variability (I2 statistic) and Chi square tests 24, 25 . Higher I2 values indicate greater between-study heterogeneity. All calculations were performed with STATA software 10.1 (The Statistics/Data Analysis StataCorp. Stata statistical software: Release 9.2. College Station, Texas). We tested the consistency of the results by comparing the direction and strength of the association. We assumed that publication bias was present and did not conduct formal statistical tests to measure it 26 .
We assessed the level of evidence based on modified GRADE Working Group criteria 27, 28 . We assigned low level of evidence to data from small RCTs, or from RCTs with serious flaws in design/analysis, and from post hoc subgroup analysis. We assigned moderate level of evidence when a single large multinational study or several small RCTs reported consistent effects of the same drugs. We assigned a high level of evidence to data from multiple high quality studies that reported consistent sustained effects at least 6 months post therapy 29 . We used pooled absolute risk difference to calculate the number needed to treat and the number of events attributable to treatment per 1000 patients 29, 30 . We calculated means and 95% confidence intervals for number needed to treat as reciprocal to pooled absolute risk difference when absolute risk difference was significant 31 . We calculated means and 95% confidence intervals for treatment eventsper 1000 treated, multiplying pooled absolute risk difference by 1000. For clinical decision making we also calculated pooled rates of the outcomes and all reported in the trials adverse effects 32 with random effects models using MetaAnalyst software 33 . We based the estimated medication cost needed to achieve one specified event on recommendations for reported weekly doses and length of treatment found in the Red Book: Pharmacy's Fundamental Resource® [34] [35] [36] .
Role of the Funding Source
The Agency for Healthcare Research and Quality suggested the initial questions and provided copyright release for this manuscript. The funding source had no role in the literature searches, data analysis, conduct of the study, preparation of the review, or interpretation of the results. The funding source reviewed and approved the submitted manuscript without revisions.
RESULTS
We identified 93 relevant articles representing RCTs of interferon alfa-2b , peginterferon alfa-2a [69] [70] [71] [72] [73] of antiviral drugs on clinical outcomes and concluded that drug treatments did not improve clinical outcomes of chronic hepatitis B infection. Clinical outcomes were rarely reported, and the trials were underpowered to detect differences in mortality, liver cancer or cirrchosis 2, 4 . The results of meta-analyses with pooled relative risk, absolute risk differences, and weights from random effects models are presented in Online Appendix 1. W e s u m m a r i z e d t h e results of the RCTs into an evidence map (Table 1) . No one treatment improved all outcomes, and there was limited evidence on comparative effects. Only interferon therapies resulted in HBsAg loss, which is one of the criteria of resolved hepatitis B. One RCT demonstrated a significant increase in HBsAg loss at the end of administration of interferon alfa-2b 60 and after interferon alfa-2b with corticosteroid. Pooled analysis of two RCTs that compared steroid pretreatment followed by interferon alfa-2b to no antiviral drugs found a significant increase in HBsAg loss at the end of treatment 46, 60 .
Combined therapy of interferon alfa-2b with lamivudine resulted in HBsAg loss and HBV DNA clearance in one RCT 43 . Peginterferon alfa-2b combined with lamivudine when compared to lamivudine alone increased HBV DNA clearance and HBsAg seroconversion 95 but it also increased rate of YMDD mutations (mutation in amino acid sequence tyrosine, methionine, aspartate, aspartate) 43, 109 . Adefovir improved fibrosis and necroinflammatory scores 74, 75, 77 , and HBeAg loss 77, 78 and seroconversion 77, 78 . Evidence on the comparative effectiveness of antiviral drugs was limited. Some antiviral drugs demonstrated superior effects on intermediate markers when compared to each other but no one regime demonstrated superior benefits on all biomarkers. For instance, lamivudine compared to peginterferon alfa-2a improved HBV DNA clearance 72 but reduced HBeAg loss 72 . Entecavir compared to lamivudine improved necroinflammation in three studies 98, 99, 102 with no differences on fibrosis scores in two studies that examined this biomarker 99, 102 . Entecavir compared to lamivudine also increased the rates of HBV DNA clearance [98] [99] [100] 103 , with no differences in HBsAg 99, 103 40, 59 , and ALT normalization 60, 63 . Adefovir improved sustained ALT normalization 75, 78 and HBV DNA clearance 75 .
Pegylated interferon alfa-2a demonstrated superior sustained effects when compared to lamivudine. Pegylated interferon alfa2a vs. lamivudine improved sustained HBV DNA 72 and HBeAg clearance 72 , seroconversion 72 , and ALT normalization 71, 72 .
Pegylated interferon alfa-2a plus lamivudine improved sustained HBV DNA 72 and HBeAg seroconversion 72 and ALT normalization 71, 72 compared to lamivudine, but not pegylated interferon alfa-2 monotherapy.
Number Needed to Treat. The number needed to treat to achieve one event of improved biomarker was fewer than ten for most of the treatments (Table 2) . Examining how many patients should be treated to improve liver histology (diagnostic markers of liver cirrhosis), we found that effectiveness is comparable among antiviral drugs. For instance, monotherapy with interferon alfa-2b was needed in four patients to achieve reduction in liver histological scores in one of them 67 . We would need to treat two patients with combined therapy of interferon alfa-2b and lamivudine to achieve improvement in histological scores in one of them 44 .
Adefovir administration in four 74, 75, 77 or entecavir in seven patients 98, 99, 102 would result in reduced necroinflammation in one patient. Peginterferon alfa-2a administered in eight patients would result in sustained depression of necroinflammation in one patient when compared to lamivudine 71 . Adefovir is the only drug that reduced fibrosis scores; administration to four patients would result in reduction of fibrosis scores in one patient 74, 77 . Sustained HBV DNA clearance was associated with favorable clinical outcomes in observational studies 18, 19, 124 .
According to our analysis, sustained HBV DNA clearance in one patient would be possible if two were treated with interferon alfa-2b or adefovir or 13 with lamivudine. Sustained HBeAg loss in one patient would be achieved if four were treated with interferon alfa-2b. We would need to treat eight patients with interferon alfa-2b to have one case of s u s t a i n e d H B e A g s e r o c o n v e r s i o n . S u s t a i n e d A LT normalization could be seen in one patient when three were treated with interferon alfa-2b or four with adefovir. Viral resistant YMDD mutations would be detected in one from two treated with lamivudine patients.
Medication Cost. Finite courses of interferon were more expensive than oral drugs. Among interferon formulations, the cost of pegylated interferon alfa-2b administration was lower when compared to interferon alfa-2b or pegylated interferon alfa-2a. We estimate an average cost per patient Sustained HBeAg loss in one patient can cost $161,760 if treated with peginterferon alfa-2b, or $215,681 if treated with interferon alfa-2b, and treatment with peginterferon alfa-2a alone or combined with lamivudine will cost to three to four times more. Sustained HBeAg seroconversion in one patient would cost more than $500,000 with interferon alfa-2b and more than $770,000 with peginterferon alfa-2a combined with lamivudine. Actual costs may be less due to possible price discounts, but relative differences would remain the same.
Attributable Events. The number of events that were attributable to treatment with antiviral drugs varied across treatments (Figs. 1, 2, 3, 4, 5 ). Compared to placebo, interferon alfa-2b alone or combined with lamivudine resulted in greater improvement in histological scores and HBV DNA clearance (Fig. 1) . HBV DNA clearance was greater after adefovir treatment when compared to lamivudine and greater after telbivudine when compared to lamivudine or adefovir (Fig. 2) . Improvement in histological scores was attributable only to interferon alfa-2b combined with lamivudine therapy when compared to interferon monotherapy (Fig. 3) . One RCT demonstrated that 320 cases of resolved hepatitis B per 1000 treated would be attributable to combined administration of peginterferon alfa-2b with lamivudine vs. lamivudine alone. Sustained HBV DNA clearance in more than 400 per 1,000 treated was attributable to adefovir or interferon alfa-2b administration when compared to placebo (Fig. 4) . Sustained intermediate outcomes could be attributed to the examined treatments when compared to active control in less than 300 per 1,000 treated patients (Fig. 5) .
Absolute Rates of the Outcomes. Physicians and patients make individual decisions based on known average probabilities of clinically important benefits and harms 125 . Probabilities vary depending on individual patient characteristics that can influence the expected treatment effects 126, 127 . We have synthesized the probabilities of clinical and intermediate outcomes in HBeAg positive patients that participated in RCTs (Fig. 6) . We hesitated to use indirect statistical comparisons that have not been examined in head-to-head RCTs. For example, mortality has never been examined in placebo controlled RCTs of pegylated interferon alfa-2a; therefore, lower rates of death after active drug (0%) vs. placebo (7.1%) could not provide good evidence of better survival. However, the rates of patient outcomes after placebo could provide a reasonable estimation of baseline risk in adults with CHB. Published studies examined the effects of antiviral drugs only on selected outcomes; none of the RCTs reported all outcomes. Analyzing the rates of all outcomes from different RCTs can give a more complete estimation of drug effects. Combined treatments did not result in better outcomes when compared to monotherapy. Relapse and treatment failure were more common after active treatments than after placebo 128, 129 .
The most common adverse events during antiviral therapy included flu-like symptoms after interferon, fatigue, headache, abdominal pain, nausea, diarrhea, or laboratory abnormalities, which were reported in over 50% of patients 2, 4 . Absolute rates of adverse events (in >10% of the patients) after placebo and active treatments are presented in Online Appendix Table 2 . Direct comparisons in published RCTs reported non significant differences in serious adverse events and withdrawal rates when compared to placebo 2 . Laboratory toxicity after adefovir restricted usage of the drug in patients with impaired renal function 2 . Entecavir was better tolerated than lamivudine. Dose modifications due to neutropenia and thrombocytopenia were necessary in 50% of patients after interferon treatment 4 .
Withdrawal rates were 24% higher after interferon-alfa-2b than with no treatment 4 . Pegylated interferon-alfa-2a combined with lamivudine resulted in greater discontinuation versus placebo or lamivudine alone 4 . Patients had serious adverse events more often after combined therapy of lamivudine with interferon-alfa2b or pegylated interferon-alfa-2a than after lamivudine alone 4 . Long-term adverse drug events include reduced bone mineral density after tenofovir and moderate serum creatine phosphokinase elevations after telbivudine 130 .
DISCUSSION
For our original report, we created a comprehensive evidence map which compares absolute rates of the outcomes, number needed to treat, number attributable to treatment events, and cost of treatment. The map provides the most complete information about the comparative effectiveness of antiviral drugs and can be used for decision-making in clinical settings.
At the present time, decision-making in clinical settings is based on the published guidelines. Current guidelines recommend finite treatment with pegylated interferon alfa or nucleos (t)ides analogs based on rates of HBV DNA clearance and HBs Ag seroconversion 131, 132 . The recommendations of the European Association for the Study of the Liver are based on the rates of HBeAg seroconversion and HBV DNA clearance from individual studies and do not differentiate benefits, harms, and cost among different interferon alfa or nucleos(t)ides analogs 131 . Our present analysis and the evidence map we created gives clinicians data on the comparative effectiveness of each therapy on intermediate outcomes. It includes the number needed to treat to achieve the selected outcome. The evidence map also identifies gaps in our knowledge about sustained effects from antiviral drugs on clinical outcomes, liver histology, resolved HBV infection, and consistent improvement in virologic and biochemical outcomes. The map suggests that future research should investigate a balance between long term benefits and harms from both mono and combined therapy. The next step in our analyses was to estimate the number needed to treat in order to inform clinicians about the effectiveness of antiviral drugs. For instance, sustained HBV DNA clearance in one patient can be achieved when two are treated with interferon alfa-2b or adefovir, but they would need to treat 13 with lamivudine.
Clinicians can then compare harms. Viral resistant YMDD mutations would be detected in one of two patients treated with lamivudine 43, 109 . Adefovir is contraindicated in patients with impaired renal function 2 . Around 21% of patients treated with interferon alfa-2b would require reduction in dose due to adverse events 37 . Clinicians now have actionable information about anticipated benefits and harms from antiviral drugs and laboratory parameters to monitor during and after the treatments. Our analyses also provide patients with information about rates of improvement in intermediate markers (Fig. 6 ) and harms of each available treatment (Online Appendix 2). Patients should be informed that no good evidence exists about preventive effects of the drugs against liver cancer or cirrhosis, the rates of sustained HBV DNA loss are 14% after peginterferon alfa-2A and 19.4% after interferon alfa-2B but both drugs caused fever in 57-61% of the patients respectively.
The costs of oral antiviral drugs are lower than that of interferon, but a more complete cost estimation should include the price of treatment of adverse effects, e.g. cost of long term osteopenia after treatment with tenofovir, or elevations in serum creatine phosphokinase after telbivudine 130 .
Our analysis uncovered a lack of good evidence from RCTs that antiviral drugs prevent cirrhosis, liver decompensation, cancer, or mortality. Few studies were specifically designed to assess these clinical outcomes; most were intended to assess the relatively short-term effects of therapies on intermediate virological, histological, or biochemical outcomes. Observational studies suggested a strong positive association between viral load and liver fibrosis with clinical outcomes 124 . Low or undetectable DNA, however, did not eliminate the risk of liver cancer or cirrhosis 124 . Furthermore, observational studies could not provide a valid estimation of drug-induced reductions in viral level in association to improved clinical outcomes 124 . Therefore, we hesitated to predict drug prevention of clinical outcomes based on observed effects on biomarkers. Previously published cost-effectiveness analyses relied on assumptions from available natural history data 133, 134 . We avoided such assumptions and used the results from RCTs that could establish causality between drug administration on intermediate outcomes. Additional costs for patients with treatment failure, relapse, or adverse events are unknown.
Limitations
As noted above, almost all studies were designed to assess the relatively short-term comparative effectiveness of the drugs on intermediate laboratory markers, not clinical outcomes. We could not find high quality evidence that antiviral drugs prevent liver carcinoma or death. One large RCT of 651 patients with advanced liver disease reported that lamivudine compared to placebo reduced the rates of the combined end point of disease progression, which was defined as the first occurrence of any of the following: an increase of at least two points in the Child-Pugh score, spontaneous bacterial peritonitis with proven sepsis, renal insufficiency, bleeding, gastric or esophageal varices, development of hepatocellular carcinoma, or death related to liver disease (34/436 in lamivudine vs. 38/215 in placebo group, hazard ratio 0.45, P=0.001) 109 . However, the effects on liver cancer was either borderline (p=0.047) or not significant (p=0.052) when the authors excluded five patients who developed hepatocellular carcinoma during the first year of the study 109 
